HR8630Referred to Committee

PEAT Act of 2026

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2026-04-30
Introduced
10
Cosponsors
HR
ⓘ
Type

Sponsor

Michael A. Rulli
Michael A. Rulli
Republican · OH · Representative
Votes with party: 96.2% (572 recorded votes)

Full profile: /officials/R000619

Source: Congress.gov · FEC

Cosponsors (10)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Referred to the House Committee on Energy and Commerce.

2026-04-30

Source: Congress.gov

Committee Activity

Currently in

Previously

Plain-English Summary

The proposal would change how the government classifies certain medications made from living cells or organisms, preventing regulators from treating a drug as a biologic product just because it contains a protein that doesn't actually affect how the medicine works. This could affect pharmaceutical companies by potentially allowing some drugs to be classified under simpler approval pathways rather than the more complex biologic drug process. The change aims to streamline drug development and approval for medications where inactive proteins are present but not medically relevant.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Subjects

Health

Full Bill Text

Verbatim text published on Congress.gov via GovInfo. Use Cmd+F / Ctrl+F to search within this excerpt.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 8630 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 8630 To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES April 30, 2026 Mr. Rulli (for himself and Mrs. Harshbarger) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Protecting Equal Access to Thyroid Act of 2026'' or the ``PEAT Act of 2026''. SEC. 2. PROHIBITION WITH RESPECT TO TREATMENT OF PROTEINS IN BIOLOGICS. (a) In General.--Section 351(i)(1) of the Public Health Service Act (42 U.S.C. 262(i)(1)) is amended-- (1) by striking ``The term'' and inserting the following: ``(A) The term''; and (2) by adding at the end the following: ``(B) A biologic described in subparagraph (A) may not be treated as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic.''. (b) Technical Correction.--Section 351(i)(1) of the Public Health Service Act (42 U.S.C. 262(i)(1)) is amended in subparagraph (A), as designated by subsection (a)(1), by striking ``protein ,'' and inserting ``protein,''. <all>
Open clean-text viewRead on Congress.gov →

Related legislation

Bills by the same sponsor or covering overlapping subjects.